Atlas Trials

A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy

Clinical trial NCT04866108 · UNKNOWN

Trial details

NCT number
NCT04866108
Sponsor
Beijing Friendship Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Unresectable Metastatic Colorectal Cancer
Start date
2021-12-08
Primary completion
2024-06-01
Enrollment
49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.